November 23, 2016 - By Darrin Black
In a note sent to investors on today, Maxim Group kept their “Buy” rating on Juno Therapeutics (NASDAQ:JUNO)‘s stock. The PT suggests a potential upside of 53.85% from company’s last stock price.
Out of 9 analysts covering Juno Therapeutics Inc (NASDAQ:JUNO), 7 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 78% are positive. $73 is the highest target while $39 is the lowest. The $51.80 average target is 134.28% above today’s ($22.11) stock price. Juno Therapeutics Inc has been the topic of 18 analyst reports since July 22, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by Citigroup given on Thursday, February 25. The rating was downgraded by JP Morgan on Friday, July 8 to “Neutral”. The stock of Juno Therapeutics Inc (NASDAQ:JUNO) earned “Buy” rating by Standpoint Research on Tuesday, December 15. Northland Capital initiated the stock with “Outperform” rating in Wednesday, July 22 report. Maxim Group maintained the shares of JUNO in a report on Friday, August 5 with “Buy” rating. The stock has “Neutral” rating given by Goldman Sachs on Wednesday, November 18. Raymond James initiated Juno Therapeutics Inc (NASDAQ:JUNO) on Thursday, June 2 with “Outperform” rating. The stock of Juno Therapeutics Inc (NASDAQ:JUNO) has “Outperform” rating given on Friday, July 8 by FBR Capital. Barclays Capital initiated Juno Therapeutics Inc (NASDAQ:JUNO) on Wednesday, July 6 with “Equal-Weight” rating. Suntrust Robinson initiated the stock with “Buy” rating in Friday, January 29 report.
About 14.48 million shares traded hands or 898.62% up from the average. Juno Therapeutics Inc (NASDAQ:JUNO) has declined 32.60% since April 21, 2016 and is downtrending. It has underperformed by 37.93% the S&P500.
Insitutional Activity: The institutional sentiment increased to 1.4 in 2016 Q2. Its up 0.06, from 1.34 in 2016Q1. The ratio improved, as 25 funds sold all Juno Therapeutics Inc shares owned while 36 reduced positions. 23 funds bought stakes while 59 increased positions. They now own 44.56 million shares or 5.68% more from 42.17 million shares in 2016Q1.
First Washington accumulated 39,700 shares or 0.88% of the stock. Omers Administration accumulated 48,500 shares or 0.04% of the stock. Principal Fincl Grp Inc Inc last reported 0% of its portfolio in the stock. Temasek (Private) reported 915,750 shares or 0.28% of all its holdings. The United Kingdom-based Pictet Asset Mngmt has invested 0.03% in Juno Therapeutics Inc (NASDAQ:JUNO). Co Of Vermont holds 0% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO) for 145 shares. Raymond James Financial Services Inc accumulated 0% or 8,871 shares. Bnp Paribas Arbitrage holds 14,678 shares or 0% of its portfolio. Eventide Asset Limited Liability owns 90,000 shares or 0.21% of their US portfolio. Ibm Retirement Fund holds 6,342 shares or 0.01% of its portfolio. Federated Pa last reported 27,614 shares in the company. Mycio Wealth Prtnrs accumulated 500 shares or 0% of the stock. Moreover, Sg Americas Limited Liability Corp has 0% invested in Juno Therapeutics Inc (NASDAQ:JUNO) for 3,978 shares. Vanguard Gru, a Pennsylvania-based fund reported 5.47 million shares. Rockefeller Finance has 0% invested in the company for 226 shares.
Juno Therapeutics, Inc. is a biopharmaceutical firm focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The company has a market cap of $2.22 billion. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. It currently has negative earnings. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas.
According to Zacks Investment Research, “Juno Therapeutics, Inc. is a biopharmaceutical company. The Company develops cellular immunotherapies based on two platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL whose cancer has recurred after a bone marrow transplant; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. Juno Therapeutics, Inc. is headquartered in Seattle, Washington.”
Juno Therapeutics, Inc. (Juno), incorporated on August 5, 2013, is a biopharmaceutical firm focused on re-engaging the bodyâ€™s immune system to revolutionize the treatment of cancer. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. The Company’s CAR and TCR technologies alter T cells ex vivo, or outside the body. In addition, the Company holds license to vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers.
More recent Juno Therapeutics Inc (NASDAQ:JUNO) news were published by: Fortune.com which released: “Juno Therapeutics’ Shares Sink After 2 More Deaths in Leukemia Drug Trial” on November 23, 2016. Also Marketwatch.com published the news titled: “UPDATE: Juno Therapeutics plummets 30% in pre-market trade after two patient …” on November 23, 2016. Fool.com‘s news article titled: “Better Buy: Ziopharm Oncology, Inc. vs. Juno Therapeutics” with publication date: November 03, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Darrin Black